Sesen Bio Stockholders Approve Merger with Carisma Therapeutics
Declares Special Dividend in the Aggregate of $75 Million Approximately 88% Voted in Favor of the Merger at the Special Meeting Merger on Track to Close on March 7, 2023 CAMBRIDGE, Mass., March 02, 2023--(BUSINESS WIRE)--Sesen Bio, Inc. (Nasdaq: SESN) ("Sesen Bio" or the "Company"), today announc...